Regulus Therapeutics (RGLS) said Thursday it has completed its phase 1b clinical trial of farabursen for the treatment of autosomal dominant polycystic kidney disease, with full data from the fourth cohort confirming the 300mg fixed dose selection to achieve optimal kidney exposure.
The company said that over four months, patients treated with 300 mg farabursen experienced a mean halting in the growth of height-adjusted total kidney volume, which has been shown to inversely correlate with kidney function.
The final efficacy data, together with the previously announced favorable safety and tolerability profile, confirm that 300 mg is appropriate for the phase 3 pivotal trial, the company said.
The company said it is on track to start the phase 3 single pivotal trial in Q3.
Shares of Regulus Therapeutics rose 55% in recent trading Thursday.
Price: 2.00, Change: +0.71, Percent Change: +54.96
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。